Black Diamond Therapeutics Inc (BDTX)
2.62
-0.23
(-8.07%)
USD |
NASDAQ |
Nov 15, 16:00
2.63
+0.01
(+0.38%)
After-Hours: 20:00
Black Diamond Therapeutics Research and Development Expense (TTM): 54.30M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 54.30M |
| June 30, 2024 | 57.54M |
| March 31, 2024 | 58.14M |
| December 31, 2023 | 59.35M |
| September 30, 2023 | 58.67M |
| June 30, 2023 | 58.36M |
| March 31, 2023 | 61.40M |
| December 31, 2022 | 64.44M |
| September 30, 2022 | 69.49M |
| June 30, 2022 | 81.27M |
| March 31, 2022 | 91.80M |
| Date | Value |
|---|---|
| December 31, 2021 | 96.83M |
| September 30, 2021 | 94.92M |
| June 30, 2021 | 80.22M |
| March 31, 2021 | 63.68M |
| December 31, 2020 | 48.21M |
| September 30, 2020 | 37.91M |
| June 30, 2020 | 30.62M |
| March 31, 2020 | 26.09M |
| December 31, 2019 | 21.75M |
| September 30, 2019 | 16.67M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
21.75M
Minimum
Dec 2019
96.83M
Maximum
Dec 2021
60.75M
Average
59.01M
Median
Research and Development Expense (TTM) Benchmarks
| Regeneron Pharmaceuticals Inc | 4.897B |
| Vanda Pharmaceuticals Inc | 78.93M |
| Ligand Pharmaceuticals Inc | 22.49M |
| Agios Pharmaceuticals Inc | 295.96M |
| ADMA Biologics Inc | 1.868M |